Acute Generalized Exanthematous Pustulosis following SARS-CoV-2 Virus: Remdesivir as a Suspected Culprit

Fatemeh Mohaghegh, Parvaneh Hatami, Zeinab Aryanian, Farahnaz Fatemi, and Zeinab Mohseni Afshar

1Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
3Department of Dermatology, Babol University of Medical Sciences, Babol, Iran
4Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

Correspondence should be addressed to Zeinab Mohseni Afshar; z_moseni2001@yahoo.com

Received 14 May 2022; Revised 23 July 2022; Accepted 30 July 2022; Published 10 August 2022

Acute generalized exanthematous pustulosis (AGEP) is an exanthematous condition, predominantly occurring as a result of drug reactions. We, hereby, present the first case of AGEP following treatment with remdesivir in a patient with COVID-19, without hydroxychloroquine use, which serves as a reminder to consider remdesivir as a possible causative agent when dealing with AGEP presentation in COVID patients.

1. Introduction

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been well-known for its multisystemic involvement; besides respiratory manifestations, mucocutaneous symptoms have been among the most common presentations of SARS-CoV-2 infection [1]. Cutaneous manifestations of SARS-CoV-2 infection can range from erythematous or maculopapular eruptions and urticaria to blisters, petechiae, and livedo reticularis [2]. Skin involvement can occur as the sole manifestation of COVID-19 infection, intervene during the course of infection, or appear after the infection has subsided [3, 4]. On the other hand, cutaneous reactions can be a manifestation of a new-onset dermatosis or an exacerbation of an existing condition [5]. The underlying cause of this phenomenon can be the virus’s direct invasion into the skin and mucosal surfaces, the immunologic inflammatory response elicited by the virus, or the side effects of therapeutics used in the settings of SARS-CoV-2 infection [6, 7].

Acute generalized exanthematous pustulosis (AGEP) is an exanthematous condition with an abrupt onset, which predominantly occurs as a result of a drug reaction. In fact, other factors such as infections, vaccinations, chemicals contact, and insect bites can also be triggering factors for AGEP [5]. Since the beginning of the COVID-19 pandemic, an increased rate of AGEP has been reported, which could be attributed to the high prevalence of the SARS-CoV-2 virus as the causative pathogen, or the result of medications used in these settings. Here, we report a case of COVID-19 associated with AGEP with significant diagnostic challenges and complications, and we present a brief literature review.

2. Case Presentation

A 62-year-old woman presented to the dermatology clinic with a generalized pruritic skin rash. She mentioned a history of SAR-CoV-2 infection one month earlier, for which she had undergone remdesivir treatment. Two days after the completion of treatment, she developed cutaneous
reactions beginning in the trunk and extending to the extremities. She also mentioned a history of Addison’s disease, for which she was taking prednisolone and fludrocortisone. On physical examination, widespread pustular eruptions with an erythematous base were covering all of her body surfaces except for the head and the neck area (Figure 1). The hair and nails were intact. No mucosal involvement was detected. She was started on high-dose oral prednisolone and cyclosporine in conjunction with acitretin and topical emollient. A few days later, she returned to the clinic with fever and toxicity. Laboratory evaluation revealed thrombocytopenia and transaminitis. Therefore, we admitted her for further workup. We initially stopped all the drugs she was taking, including cyclosporine and acitretin, and took a skin biopsy.

The histopathology report was indicative of linear neutrophilic parakeratosis with mild acanthosis and focal spongiosis, along with scattered necrotic keratinocytes, ectatic capillaries, and perivascular interstitial lymphocytic and eosinophilic infiltration in the dermis, all compatible with the diagnosis of AGEP (Figure 2). Then, we started her on methylprednisolone pulse and IVIG due to the possibility of idiopathic thrombocytopenia (ITP) in this patient. She was tested negative for COVID-19 and HIV-Ab. The chest CT scan, as was expected, showed diffuse ground-glass opacities in both the lungs compatible with a convalescent pulmonary phase of SARS-CoV-2 infection (Figure 3). Three days after the initiation of intensive therapy, platelet counts increased and liver enzymes decreased. The eruptions rapidly resolved within a few days; therefore, we switched the therapy to intravenous hydrocortisone and then to prednisolone with gradual tapering. At the time of discharge, postpustular desquamation was demonstrated. At follow-up visits, the patient did not describe any relapses.

3. Discussion

Acute generalized exanthematous pustulosis (AGEP) is an acute pustular dermatosis with the abrupt onset of a great number of pustules with edematous and erythematous bases [8].

Several conditions, including infections, vaccination, and medications, have been mentioned as precipitating factors of AGEP [9]. The COVID-19 pandemic has unveiled a wide range of dermatologic disorders, new-onset or flare, in SARS-CoV-2 infected patients. Therefore, this virus should also be listed among the infectious causes of AGEP [10].

Medications most commonly associated with AGEP include pristinamycin, aminopenicillins, fluoroquinolones, antimalarials, sulfonamides, terbinafine, azoles, protease inhibitors, dapsone, pantoprazole, diltiazem, corticosteroids, azithromycin, NSAIDs, and antiepileptic agents [8].
Among the common therapeutics used during a SARS-CoV-2 infection with the probability of inducing AGEP, we can name hydroxychloroquine, which is the most notorious medication for inducing AGEP, favipiravir, azithromycin, NSAIDs, protease inhibitors such as lopinavir-ritonavir, anticoagulants, and glucocorticoids [11–19]. Our patient had received azithromycin, dexamethasone, naproxen, and remdesivir for SARS-CoV-2 infection. Therefore, the onset of AGEP could be attributed to any of the mentioned agents, although there has been no definite report of remdesivir-associated AGEP.

In AGEP, the duration of drug exposure before the onset of the symptoms varied from a few hours to a few weeks depending on the causative drug [17]. Our case presented with AGEP 4 weeks after receiving COVID treatment, which was a longer latency period compared to AGEP reported in COVID-19 infected patients in the recent literature, which makes it difficult to attribute the AGEP to these medications. However, one can infer that the combination of each of these medications, including remdesivir and genetic disposition with COVID-19 induced cytokine storm, led to the delayed development of AGEP in this case. In fact, AGEP is a hypersensitivity reaction mediated by CD8+/CD4 + T cells. Keratinocyte apoptosis occurs secondary to the migration of drug-specific T cells to the skin via granzyme B and the Fas ligand mechanism [20].

Moreover, interferon-gamma and granulocyte/macrophage colony-stimulating factors released by the drug-specific T cells could lead to prolongation of the process [21].

Though AGEP might be considered as an unreported side effect of remdesivir, which has been widely used during the COVID era, it could be merely the result of the resemblance of inflammatory cytokine cascade alterations in the setting of both COVID-19 and AGEP, which let us consider these lesions as some late-onset cutaneous manifestations of COVID-19 [22]. Further reports will shed more light on this issue.

Eliminating the causative trigger, such as ceasing the drug or treating the infection, is the cornerstone of AGEP management. Other potentially useful options include moist dressings and topical antiseptics, systemic antibiotics if superinfection intervenes, and topical or systemic corticosteroids [23, 24]. However, in severe or recalcitrant cases, cyclosporine and intravenous immunoglobulin may be beneficial [25].

4. Conclusion

We reported a case of AGEP, which might have been triggered by COVID-19 infection itself or be considered as an unreported possible side effect of remdesivir, to emphasize the necessity of paying more attention to history-taking and clinical suspicion as key factors to reaching the correct diagnosis [26–31]. Furthermore, one can infer from our report that when dealing with skin findings, remdesivir should be kept in mind as a causative agent.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Additional Points

Key Clinical Message. The authors presented the first case of AGEP following treatment with remdesivir in a patient with COVID-19 without hydroxychloroquine use which could be an important issue when dealing with cutaneous rashes, considering the widespread use of remdesivir in the COVID era.

Ethical Approval

Ethical approval from the Medical Ethics Committee of Isfahan University of Medical Sciences was provided.

Consent

Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

F.M visited the patient. F.M and P.H. gathered the data. F.F supervised the project. Z.M and Z.A. provided the initial draft. P.H and Z.A wrote the final version. All the authors discussed the results.

Acknowledgments

The authors thank Parto Noor Aseman Company (http://www.parnoa.ir) staff who further observed and scanned stained skin sections using the Microvisioneer manual whole slide imaging and the Razi Hospital Clinical Research Development Center and the Autoimmune Bullous Diseases Research Center for their technical and editorial assistance.

References

[1] P. Suchonwanit, K. Lerteunyakul, and C. Kositkuljorn, “Cutaneous manifestations in COVID-19: lessons learned from current evidence,” Journal of the American Academy of Dermatology, vol. 83, no. 1, Article ID e57, 2020.
[2] Z. Mohseni Afshar, A. Babazadeh, A. Hasanpour, M. Barary, B. Sayad, and A. Janbakhsh, “Dermatological manifestations associated with COVID-19: a comprehensive review of the current knowledge,” journal of Medical Virology, vol. 93, no. 10, pp. 5756–5767, 2021.
[3] B. Panambur and S. B. Kakkilaya, “Palmar erythema as the sole manifestation of COVID-19,” Cureus, vol. 12, no. 11, 2020.
[4] C. Rodriguez-Cerdeira, B. I. Uribe-Camacho, L. Silverio-Carrasco, W. Méndez, A. R. Mahesh, and A. Tejada,
“Cutaneous manifestations in COVID-19: report on 31 cases from five countries,” *Biolog*, vol. 10, no. 1, p. 54, 2021.

[5] R. Miladi, A. Janbaksh, A. Babazadeh, Z. Aryanian, S. Ebrahimpour, and M. Barary, “Pustular psoriasis flare-up in a patient with COVID-19,” *Journal of Cosmetic Dermatology*, vol. 20, no. 11, pp. 3364–3368, 2021.

[6] N. Novak, W. Meng, M. C. Naegeli, C. Galvan, I. Kolm-Djamei, and C. Brüggen, “SARS-CoV-2, COVID-19, skin and immunology—What do we know so far?,” *Allergy*, vol. 76, no. 3, pp. 698–713, 2021.

[7] P. Gisondi, S. Plaseric, C. Bordin, M. Alaibac, G. Girolomoni, and L. Naldi, “Cutaneous manifestations of SARS-CoV-2 infection: a clinical update,” *Journal of the European Academy of Dermatology and Venereology*, vol. 34, no. 11, pp. 2499–2504, 2020.

[8] A. Sidoroff, A. Dunant, C. Viboud et al., “Risk factors for acute generalized exanthematous pustulosis (AGEP)—results of a multinational case–control study (EuroSCAR),” *British Journal of Dermatology*, vol. 157, no. 5, pp. 989–996, 2007.

[9] K. Hoegler, A. John, M. Händler, and R. Schwarz, “Generalized pustular psoriasis: a review and update on treatment,” *Journal of the European Academy of Dermatology and Venereology*, vol. 32, no. 10, pp. 1645–1651, 2018.

[10] F. Mashayekhi, F. Seirafianpour, A. Pour Mohammad, and S. Ebrahimpour, “Acute generalized exanthematous pustulosis induced by paracetamol,” *Dermatology*, vol. 193, no. 4, pp. 338–341, 1996.

[11] J. Ghosn, C. Duvivier, R. Tubiana, C. Katlama, and E. Caumes, “Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir,” *Clinical Infectious Diseases*, vol. 41, no. 9, pp. 1360–1361, 2005.

[12] A. De Coninck, A. Van Struabar, M. Pipeleers-Marichal, L. Huyghens, E. Suys, and D. Roseeuw, “Acute generalized exanthematous pustulosis induced by paracetamol,” *Dermatology*, vol. 139, no. 4, pp. 338–341, 1996.

[13] J. Vettorazzi, E. G. Valério, M. L. Kayser, L. G. Pezzali, D. V. Vettori, and G. F. Rostirolla, “Acute generalized exanthematous pustulosis during puerperal period induced by azithromycin: case report,” *Open Journal of Obstetrics and Gynecology*, vol. 08, no. 12, pp. 1156–1162, 2018.

[14] J. Delaleu, B. Deniau, M. Battistella et al., “Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19,” *Journal of Allergy and Clinical Immunology: In Practice*, vol. 8, no. 8, pp. 2777–2779, 2020.

[15] K. Bailey, D. Mckee, J. Wismer, and N. Shear, “Acute generalized exanthematous pustulosis induced by hydroxychloroquine: first case report in Canada and review of the literature,” *Journal of Cutaneous Medicine and Surgery*, vol. 17, 2013.

[16] U. Buetstiker, M. Keller, W. J. Pichler, L. R. Braathen, and N. Yawalkar, “Oral prednisolone induced acute generalized exanthematous pustulosis due to corticosteroids of group A confirmed by epicutaneous testing and lymphocyte transformation tests,” *Dermatology*, vol. 213, no. 1, pp. 40–43, 2006.

[17] M. F. Atak, B. Farabi, A. Akbayrak, M. B. Kalelioğlu, and B. K. Rao, “Acute generalized exanthematous pustulosis following treatment with favipiravir in A patient with COVID-19 without hydroxychloroquine use: report of the first case,” *Journal of Cosmetic Dermatology*, vol. 20, no. 8, pp. 2387–2389, 2021.

[18] J. Yates, M. Choudhry, and G. Keys, “A case report describing a suspected rivaroxaban hypersensitivity reaction in a surgical patient,” *Journal of Clinical Pharmacy and Therapeutics*, vol. 38, no. 2, pp. 159–161, 2013.

[19] M. Daye and P. Oltulu, “An AGEP case due to COVID-19 or favipiravir or enoxaparin,” *Journal of Cosmetic Dermatology*, vol. 21, no. 1, pp. 13–15, 2022.

[20] S. Schmid, P. C. Kuechler, M. Britschgi et al., “Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation,” *American Journal of Pathology*, vol. 161, no. 6, pp. 2079–2086, 2002, http://www.ncbi.nlm.nih.gov/pubmed/12466124.

[21] J. Szatkowski and R. A. Schwartz, “Acute generalized exanthematous pustulosis (AGEP): a review and update,” *Journal of the American Academy of Dermatology*, vol. 73, no. 5, pp. 843–848, 2015.

[22] A. Ayatollahi, R. M. Robati, K. Kamyab, and A. Firooz, “Late-onset AGEP-like skin pustular eruption following COVID-19: a possible association,” *Dermatologic Therapy*, vol. 33, no. 6, Article ID e14275, 2020.

[23] S. Ingen-Housz-Oro, C. Hotz, L. Valeyrie-Allanore et al., “Acute generalized exanthematous pustulosis: a retrospective audit of practice between 1994 and 2011 at a single centre,” *British Journal of Dermatology*, vol. 172, no. 5, pp. 1455–1457, 2015.

[24] H. Y. Lee, D. Chou, S. M. Pang, and T. Shirmourouthy, “Acute generalized exanthematous pustulosis: analysis of cases managed in a tertiary hospital in Singapore,” *International Journal of Dermatology*, vol. 49, no. 5, pp. 507–512, 2010.

[25] M. A. Hadavand, B. Kaffengerber, A. M. Cartron, and J. C. Trinidad, “Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis (AGEP),” *Journal of the American Academy of Dermatology*, 2020.

[26] Z. Nikyar, P. Hatami, Z. Aryanian, K. Kamyab Hesari, A. Goodarzi, and A. Borzuoei, “Coeexistence of neonatal lupus erythematosus and sturge-weber syndrome,” *Case Report in Dermatological Medicine*, vol. 2021, Article ID 3616429, 5 pages, 2021.

[27] F. Mohaghegh, P. Hatami, M. Saber et al., “Unusual presentations of cutaneous leishmaniasis: pearls for correct diagnosis,” *International Journal of Dermatology*, vol. 61, no. 5, pp. 618–620, 2022.

[28] M. Akhyani, P. Hatami, Z. Yadegarfar, and A. Ghanadan, “Pigmented colloid milium associated with exogenous ochronosis in a farmer with long-term exposure to fertilizers,” *Journal of Dermatology Case Report*, vol. 9, no. 2, pp. 42–45, 2015.

[29] Y. Kalantari, A. Sadeghzadeh-Bazargan, Z. Aryanian, P. Hatami, and A. Goodarzi, “First reported case of delayed-type hypersensitivity reaction to non-hyaluronic acid Polycaprolactone dermal filler following COVID-19 vaccination: a case report and a review of the literature,” *Clinical Case Report*, vol. 10, no. 2, Article ID e05343, 2022.

[30] F. Mohaghegh, P. Hatami, and Z. Aryanian, “Case of atypical disseminated herpes zoster in a patient with COVID-19: a diagnostic challenge in COVID era,” *Clinical Case Reports*, vol. 10, no. 2, Article ID e05342, 2022.

[31] F. Torkashvand, M. Rezaeian, M. Sheikh Fathollahi, S. Yazdi, P. Koochak, R. A. Karimi, S. Mohammadreza Khatanezad, P. Hatami, and R. Bidaki, “A survey on psychiatric disorders in patients improved on psychiatric medications from five countries,” *Biolog*, vol. 10, no. 1, p. 54, 2021.